Nomograms demonstrated strong predictive performance, with C-indexes around 0.70 to 0.72 and 5- and 10-year areas under the curve ranging from 0.713 to 0.759 in training and validation cohorts.

Undetectable measurable residual disease rates can help predict progression-free survival in patients with chronic lymphocytic leukemia, according to an analysis. A recent study highlights the ...

Secondary immunodeficiency disease (SID) status was associated with significantly higher risk for severe bacterial infections in adult patients with chronic lymphocytic leukemia (CLL)/small ...

Calquence and Venclexta, with or without Gazyva, improved PFS in untreated CLL patients compared to standard chemoimmunotherapy. The AMPLIFY trial showed reduced disease progression risk with the ...

Researchers at the University of Eastern Finland and their international collaborators have identified key developmental and ...

Today, Pharmacyclics LLC, an AbbVie company, announced that ibrutinib (IMBRUVICA®) improved progression-free survival (PFS; primary endpoint) and multiple secondary endpoints including overall ...

Researchers sought to determine whether zanubrutinib would be effective for patients with CLL/SLL who were intolerant to other BTK inhibitors.

Jaypirca is a targeted therapy for CLL and other specific cancers. It is known as a Bruton’s tyrosine kinase inhibitor (BTK inhibitor). BTK is an enzyme that helps certain types of cancer cells grow.

What study showed data for zanubrutinib in previously untreated CLL? Mazyar Shadman, MD, MPH: The SEQUOIA study was a larger ...

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, advances its vision to become the world’s leading oncology company with extensive new data from its ...

Researchers at the University of Eastern Finland and their international collaborators have identified key developmental and ...

Copiktra (duvelisib) is a type of cancer treatment for certain people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are slow-growing cancers that affect a ...